Epilepsy affects more than 60 million people around the world. Despite obtaining two or more approved drug therapies, more than 40% of patients develop medication resistance throughout their illness. This results in a distressing rise in seizures. Pharma co-resistance is the term for this. Pharma co-resistance develops in about 20% of patients with primary generalized epilepsy and up to 60% of patients with focal epilepsy.

Helping The Brain In The Best Way Out

The brain is without a doubt the most complex organ in the human body. A complex network of billions of neurons connected by electrical circuits. Serotonin is a neurotransmitter that helps the brain work normally. Imbalances often cause mental health issues and neurological ailments. The Bright Minds Biosciences team is dedicated to developing the next generation of serotonin drugs that can specifically target particular conditions, resulting in a significant reduction in side effects and increased clinical action, ultimately changing the lives of patients.

Serotoninergic medications may be used to treat pharma co-resistant epilepsy in rare genetic disorders, including Dravet Syndrome and Lennox-Gastaut Syndrome. Still, these drugs also have severe side effects due to non-specific activity on the 5-HT2B receptor, necessitating close monitoring and dosing restrictions.

Best Medications For Healing To The Core

Several licensed medications, such as carbamazepine and valproate, increase local serotonin concentrations in the brain, helping control seizures in part. Serotonin agonists can control seizures in neurons and promote neuronal survival by speeding up mitochondrial function recovery after seizures and protecting the brain.

Bright Minds Biosciences has a specific pipeline of 5-HT2C agonists being tested for epilepsy treatment. Research is currently underway in conjunction with the National Institutes of Health to identify the best compound for epilepsy treatment.

Healing Patients With Neuropathy

Anxiety, depression, and cognitive dysfunction are common symptoms in patients with chronic pain. Patients with these chronic pain syndromes are underserved by currently available approved treatments, and they often turn to unapproved psychedelics and opiates for pain relief.

Giving Life To The Chronic Pain Sufferers

Today's chronic pain patients face a shortage of choices, which sometimes forces them to choose between highly addictive medications and continued pain. In animal models of many difficult-to-treat painful syndromes, such as cluster headache, fibromyalgia, and chemotherapy-induced peripheral neuropathy, serotonin agonists have been shown to have potent results in suppressing painful sensations.

Effective drugs for efficient treatments

These patients need more effective and less dangerous medications that will help them manage their pain and improve their quality of life. 5-HT2C/A agonists' neuropsychiatric and analgesic effects are expected to lead to improved pain relief without the addiction, drowsiness, and worsened memory associated with current pain medications.

Bright Minds Biosciences is collaborating with the National Institutes of Health to create new non-opioid pain relievers.

Conclusion

Cognitive function, emotions, memory, and the sleep-wake cycle are all regulated by serotonin (5-HT) receptors. Serotonin system dysfunction is linked to various diseases, including neuropsychiatric, seizure, and pain disorders. Bright Minds' compounds are intended to restore natural levels of basic serotonin production.